Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Computational systems biology approaches to anti-angiogenic cancer therapeutics.

Literature DB >> 25286370

Computational systems biology approaches to anti-angiogenic cancer therapeutics.

Stacey D Finley¹, Liang-Hui Chu², Aleksander S Popel².

Abstract

Angiogenesis is an exquisitely regulated process that is required for physiological processes and is also important in numerous diseases. Tumors utilize angiogenesis to generate the vascular network needed to supply the cancer cells with nutrients and oxygen, and many cancer drugs aim to inhibit tumor angiogenesis. Anti-angiogenic therapy involves inhibiting multiple cell types, molecular targets, and intracellular signaling pathways. Computational tools are useful in guiding treatment strategies, predicting the response to treatment, and identifying new targets of interest. Here, we describe progress that has been made in applying mathematical modeling and bioinformatics approaches to study anti-angiogenic therapeutics in cancer.

Entities: CellLine Chemical Disease Gene Species

Mesh：

Substances：
Angiogenesis Inhibitors

Year: 2014 PMID： 25286370 PMCID： PMC4336587 DOI： 10.1016/j.drudis.2014.09.026

Source DB: PubMed Journal: Drug Discov Today ISSN： 1359-6446 Impact factor: 7.851

99 in total

1. Use of genome-wide association studies for drug repositioning.

Authors: Philippe Sanseau; Pankaj Agarwal; Michael R Barnes; Tomi Pastinen; J Brent Richards; Lon R Cardon; Vincent Mooser
Journal: Nat Biotechnol Date: 2012-04-10 Impact factor: 54.908

Review 2. MicroRNAs in vascular and metabolic disease.

Authors: Anna Zampetaki; Manuel Mayr
Journal: Circ Res Date: 2012-02-03 Impact factor: 17.367

Review 3. Dissecting cancer through mathematics: from the cell to the animal model.

Authors: Helen M Byrne
Journal: Nat Rev Cancer Date: 2010-03 Impact factor: 60.716

Review 4. Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.

Authors: Prakash Vempati; Aleksander S Popel; Feilim Mac Gabhann
Journal: Cytokine Growth Factor Rev Date: 2013-11-27 Impact factor: 7.638

5. Identifying therapeutic targets in a combined EGFR-TGFβR signalling cascade using a multiscale agent-based cancer model.

Authors: Zhihui Wang; Veronika Bordas; Jonathan Sagotsky; Thomas S Deisboeck
Journal: Math Med Biol Date: 2010-12-08 Impact factor: 1.854

Review 6. An imaging-based tumour growth and treatment response model: investigating the effect of tumour oxygenation on radiation therapy response.

Authors: Benjamin Titz; Robert Jeraj
Journal: Phys Med Biol Date: 2008-08-01 Impact factor: 3.609

7. Inhibition of lymphangiogenesis and angiogenesis in breast tumor xenografts and lymph nodes by a peptide derived from transmembrane protein 45A.

Authors: Esak Lee; Jacob E Koskimaki; Niranjan B Pandey; Aleksander S Popel
Journal: Neoplasia Date: 2013-02 Impact factor: 5.715

8. Collections of simultaneously altered genes as biomarkers of cancer cell drug response.

Authors: David L Masica; Rachel Karchin
Journal: Cancer Res Date: 2013-01-21 Impact factor: 12.701

9. Computational Model of Gab1/2-Dependent VEGFR2 Pathway to Akt Activation.

Authors: Wan Hua Tan; Aleksander S Popel; Feilim Mac Gabhann
Journal: PLoS One Date: 2013-06-21 Impact factor: 3.240

10. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.

Authors: F Loupakis; C Cremolini; A Fioravanti; P Orlandi; L Salvatore; G Masi; T Di Desidero; B Canu; M Schirripa; P Frumento; A Di Paolo; R Danesi; A Falcone; G Bocci
Journal: Br J Cancer Date: 2011-03-15 Impact factor: 7.640

27 in total

1. The impact of tumor receptor heterogeneity on the response to anti-angiogenic cancer treatment.

Authors: Ding Li; Stacey D Finley
Journal: Integr Biol (Camb) Date: 2018-04-23 Impact factor: 2.192

2. A biochemo-mechano coupled, computational model combining membrane transport and pericellular proteolysis in tissue mechanics.

Authors: A-T Vuong; A D Rauch; W A Wall
Journal: Proc Math Phys Eng Sci Date: 2017-03-08 Impact factor: 2.704

Computational systems biology approaches to anti-angiogenic cancer therapeutics.

1. Use of genome-wide association studies for drug repositioning.

Review 2. MicroRNAs in vascular and metabolic disease.

Review 3. Dissecting cancer through mathematics: from the cell to the animal model.

Review 4. Extracellular regulation of VEGF: isoforms, proteolysis, and vascular patterning.

5. Identifying therapeutic targets in a combined EGFR-TGFβR signalling cascade using a multiscale agent-based cancer model.

Review 6. An imaging-based tumour growth and treatment response model: investigating the effect of tumour oxygenation on radiation therapy response.

7. Inhibition of lymphangiogenesis and angiogenesis in breast tumor xenografts and lymph nodes by a peptide derived from transmembrane protein 45A.

8. Collections of simultaneously altered genes as biomarkers of cancer cell drug response.

9. Computational Model of Gab1/2-Dependent VEGFR2 Pathway to Akt Activation.

10. Pharmacodynamic and pharmacogenetic angiogenesis-related markers of first-line FOLFOXIRI plus bevacizumab schedule in metastatic colorectal cancer.

1. The impact of tumor receptor heterogeneity on the response to anti-angiogenic cancer treatment.

2. A biochemo-mechano coupled, computational model combining membrane transport and pericellular proteolysis in tissue mechanics.

3. Transcriptional Characterization of Compounds: Lessons Learned from the Public LINCS Data.

4. A multiscale model of complex endothelial cell dynamics in early angiogenesis.

Review 5. Systems medicine: evolution of systems biology from bench to bedside.

6. Immune cells regulate VEGF signalling via release of VEGF and antagonistic soluble VEGF receptor-1.

Review 7. Monitoring Severity of Multiple Organ Dysfunction Syndrome: New Technologies.

Review 8. Multiscale Modeling in the Clinic: Drug Design and Development.

Review 9. Multi-scale Modeling in Clinical Oncology: Opportunities and Barriers to Success.

10. Applying optimization algorithms to tuberculosis antibiotic treatment regimens.